Table 1 Recent patent applications in CRISPR-Cas systems
Patent number | Description | Assignee | Inventor | Priority application date | Publication date |
|---|---|---|---|---|---|
WO2013188037A2 | A method of processing a target RNA comprising contacting the products of an RNA ligase–mediated ligation reaction with a CRISPR-associated (Cas)6 protein, where the RNA ligase–mediated ligation reaction comprises a target RNA, an RNA ligase, and first and second adaptors that can ligate with each other to produce an adaptor dimer that contains a CRISPR stem loop; the Cas6 protein recognizes the CRISPR stem loop, thus preventing the adaptor dimer from being reverse transcribed. | Agilent Technologies (Santa Clara, CA, USA) | Zeiner G, Bruhn L | 6/11/2012 | 12/19/2013 |
US20130288251A1 | A nucleic acid comprising a Lactococcus CRISPR region, Lactococcus CRISPR spacer region and/or Lactococcus Cas gene. | DuPont Nutrition Biosciences (Copenhagen), Horvath P, Romero D, Millen AM | Horvath P, Romero D, Millen AM | 10/20/2010 | 10/31/2013 |
US8546553B2 | A method of inactivating a target polynucleotide in a microbe comprising introducing into the microbe a plasmid DNA expressing small interfering RNA (psiRNA) comprising a 5´ region and a 3´ region, where the 5´ region is a psiRNA-tag of between 5 and 10 nucleotides chosen from a repeat from a CRISPR locus immediately upstream of a spacer, where the 3´ region comprises 18–75 nucleotides, and where the 3´ region is substantially complementary to a portion of the target polynucleotide, where the target polynucleotide is inactivated. | University of Georgia Research Foundation (Athens, GA, USA), Terns R, Terns M, Hale C | Terns R, Terns M, Hale C | 7/25/2008 | 10/1/2013 |
NZ597299A | One or more Cas genes or proteins; useful for modulating resistance in a cell against a target nucleic acid or its transcription product. | DuPont Nutrition Biosciences (Copenhagen) | – | 8/26/2005 | 3/28/2013 |
RU2011122776A | An isolated nucleic acid comprising a sequence of a bifidobacteria CRISPR locus selected from a specific nucleotide. | Danisco (Copenhagen) | Barrangou R, Horvath P, Romero DA, Traeger LL | 11/7/2008 | 12/20/2012 |
US20120088676A1 | A method of typing or subtyping Salmonella bacteria, comprising amplifying a nucleic acid fragment comprising the CRISPR1 and/or CRISPR2 locus using a set of primers comprising no more than 50 nucleotides, determining the variable sequence composition of the amplified fragment, and comparing the composition with a reference comprising variable sequence compositions listed in the specification. | Institut Pasteur (Paris) | Weill FX, Fabre L, Véronique G, Laure D, Sylvain B | 12/28/2007 | 4/12/2012 |
CN102264895A | CRISPR locus from Streptococcus thermophilus containing a nucleotide sequence chosen from a sequence having a 894-bp sequence and its derivatives. | Danisco (Copenhagen) | Manoury E, Horvath P, Fremaux C, Fourcassie P | 12/12/2008 | 11/30/2011 |
US20110223638A1 | A method of generating nucleic acid fragments of substantially uniform length, involving contacting a DNA substrate with a CRISPR-Cas1 polypeptide to generate nucleic acid fragments of substantially uniform length. | Wiedenheft B, Zhou K, Doudna JA | Wiedenheft B, Zhou K, Doudna JA | 3/10/2010 | 9/15/2011 |
US20110217739A1 | A polynucleotide comprising: a nucleotide sequence (a1) encoding a polypeptide having Cas6 endoribonuclease activity, where the amino acid sequence of the polypeptide has at least 80% sequence identity to a defined amino acid sequence, or the full complement of (a1); and a heterologous polynucleotide. | University of Georgia Research Foundation (Athens, GA, USA) | Terns R, Terns MP, Carte J | 11/6/2008 | 9/8/2011 |
US20100076057A1 | A method of inhibiting the function and/or presence of a target DNA sequence in a eukaryotic cell, comprising administering CRISPR RNA (crRNA) and one or more CRISPR-Cas proteins, or nucleic acid sequences encoding the Cas proteins, to a eukaryotic cell comprising a target DNA sequence, where the crRNA hybridizes with the target DNA sequence, thus interfering with the function and/or presence of the target DNA sequence. | Northwestern University (Evanston, IL, USA) | Sontheimer EJ, Marraffini LA | 9/23/2008 | 3/25/2010 |
